{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:59:06Z","timestamp":1761947946384},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T00:00:00Z","timestamp":1390953600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s10147-014-0665-7","type":"journal-article","created":{"date-parts":[[2014,1,28]],"date-time":"2014-01-28T01:23:38Z","timestamp":1390872218000},"page":"1065-1073","source":"Crossref","is-referenced-by-count":4,"title":["Local control and prognostic significance of transarterial treatment for limited recurrence of ovarian cancer as third-line and beyond therapy"],"prefix":"10.1007","volume":"19","author":[{"given":"Akihiko","family":"Seki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Sueyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,29]]},"reference":[{"key":"665_CR1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00432-008-0488-x","volume":"135","author":"S Nishio","year":"2009","unstructured":"Nishio S, Katsumata N, Matsumoto K et al (2009) Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum\/taxane regimens as first-line therapy. J Cancer Res Clin Oncol 135:551\u2013557","journal-title":"J Cancer Res Clin Oncol"},{"issue":"Suppl 1","key":"665_CR2","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/S0020-7292(06)60033-7","volume":"95","author":"AP Heintz","year":"2006","unstructured":"Heintz AP, Odicino F, Maisonneuve P et al (2006) Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95(Suppl 1):S161\u2013S192","journal-title":"Int J Gynaecol Obstet"},{"key":"665_CR3","unstructured":"Ovarian Cancer Guideline (Version 1. 2013). National Comprehensive Cancer Network. http:\/\/www.nccn.org\/"},{"key":"665_CR4","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","volume":"22","author":"M Markman","year":"2004","unstructured":"Markman M, Markman J, Webster K et al (2004) Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 22:3120\u20133125","journal-title":"J Clin Oncol"},{"key":"665_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1525-1438.2005.15351.x","volume":"15","author":"RF Ozols","year":"2005","unstructured":"Ozols RF (2005) Treatment goals in ovarian cancer. Int J Gynecol Cancer 15:3\u201311","journal-title":"Int J Gynecol Cancer"},{"key":"665_CR6","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0360-3016(01)01733-3","volume":"51","author":"A Tinger","year":"2001","unstructured":"Tinger A, Waldron T, Peluso N et al (2001) Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma. Int J Radiat Oncol Biol Phys 51:1256\u20131263","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"665_CR7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ygyno.2005.11.047","volume":"102","author":"M Quon","year":"2006","unstructured":"Quon M, Gallant V, Samant R (2006) Effective palliative radiotherapy for symptomatic recurrent or residual ovarian cancer. Gynecol Oncol 102:204\u2013209","journal-title":"Gynecol Oncol"},{"key":"665_CR8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1872-034X.2008.00338.x","volume":"38","author":"M Yoshikawa","year":"2008","unstructured":"Yoshikawa M, Ono N, Yodono H et al (2008) Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 38:474\u2013483","journal-title":"Hepatol Res"},{"key":"665_CR9","first-page":"40","volume":"6","author":"H Onishi","year":"2000","unstructured":"Onishi H, Yamaguchi M, Kuriyama K et al (2000) Effect of concurrent intra-arterial infusion of platinum drugs for patients with stage III or IV uterine cervical cancer treated with radical radiation therapy. Cancer J Sci Am 6:40\u201345","journal-title":"Cancer J Sci Am"},{"key":"665_CR10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.lungcan.2012.04.006","volume":"77","author":"M Nakanishi","year":"2012","unstructured":"Nakanishi M, Yoshida Y, Natazuka T (2012) Prospective study of transarterial infusion of docetaxel and cisplatin to treat non-small-cell lung cancer in patients contraindicated for standard chemotherapy. Lung Cancer 77:353\u2013358","journal-title":"Lung Cancer"},{"key":"665_CR11","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.soc.2008.04.015","volume":"17","author":"KT Robbins","year":"2008","unstructured":"Robbins KT, Homma A (2008) Intra-arterial chemotherapy for head and neck cancer: experiences from three continents. Surg Oncol Clin N Am 17:919\u2013933","journal-title":"Surg Oncol Clin N Am"},{"key":"665_CR12","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00270-010-0031-8","volume":"34","author":"Y Koike","year":"2011","unstructured":"Koike Y, Takizawa K, Ogawa Y et al (2011) Transcatheter arterial chemoembolization (TACE) or embolization (TAE) for symptomatic bone metastases as a palliative treatment. Cardiovasc Intervent Radiol 34:793\u2013801","journal-title":"Cardiovasc Intervent Radiol"},{"key":"665_CR13","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3109\/00016489.2012.759275","volume":"133","author":"T Furusaka","year":"2013","unstructured":"Furusaka T, Matsuda A, Tanaka A et al (2013) Superselective intra-arterial chemoradiation therapy for functional laryngeal preservation in advanced squamous cell carcinoma of the glottic larynx. Acta Otolaryngol 133:633\u2013640","journal-title":"Acta Otolaryngol"},{"key":"665_CR14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"665_CR15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00520-009-0744-x","volume":"18","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Maitland ML, Segaert S et al (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18:509\u2013522","journal-title":"Support Care Cancer"},{"key":"665_CR16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jrr\/rrs108","volume":"54","author":"K Yahara","year":"2013","unstructured":"Yahara K, Ohguri T, Imada H et al (2013) Epithelial ovarian cancer: definitive radiotherapy for limited recurrence after complete remission had been achieved with aggressive front-line therapy. J Radiat Res 54:322\u2013329","journal-title":"J Radiat Res"},{"key":"665_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00520-002-0355-2","volume":"11","author":"H M\u00fcller","year":"2003","unstructured":"M\u00fcller H, Hilger R (2003) Curative and palliative aspects of regional chemotherapy in combination with surgery. Support Care Cancer 11:1\u201310","journal-title":"Support Care Cancer"},{"key":"665_CR18","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ygyno.2011.11.001","volume":"124","author":"TJ Vogl","year":"2012","unstructured":"Vogl TJ, Naguib NN, Lehnert T et al (2012) Initial experience with repetitive transarterial chemoembolization (TACE) as a third line treatment of ovarian cancer metastasis to the liver: indications, outcomes and role in patient\u2019s management. Gynecol Oncol 124:225\u2013229","journal-title":"Gynecol Oncol"},{"key":"665_CR19","first-page":"364","volume":"31","author":"T Chiyoda","year":"2010","unstructured":"Chiyoda T, Tsuda H, Nomura H et al (2010) Effects of third-line chemotherapy for women with recurrent ovarian cancer who received platinum\/taxane regimens as first-line chemotherapy. Eur J Gynaecol Oncol 31:364\u2013368","journal-title":"Eur J Gynaecol Oncol"},{"key":"665_CR20","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1048-891X.2004.014512.x","volume":"14","author":"S Tangjitgamol","year":"2004","unstructured":"Tangjitgamol S, See HT, Manusirivithaya S et al (2004) Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients. Int J Gynecol Cancer 14:804\u2013814","journal-title":"Int J Gynecol Cancer"},{"key":"665_CR21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejogrb.2012.10.003","volume":"166","author":"I Bruchim","year":"2013","unstructured":"Bruchim I, Jarchowsky-Dolberg O, Fishman A (2013) Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 166:94\u201398","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"665_CR22","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/annonc\/mds203","volume":"23","author":"LC Hanker","year":"2012","unstructured":"Hanker LC, Loibl S, Burchardi N et al (2012) The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy. Ann Oncol 23:2605\u20132612","journal-title":"Ann Oncol"},{"key":"665_CR23","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2217\/fon.11.55","volume":"7","author":"KM Stampler","year":"2011","unstructured":"Stampler KM, Holtz DO, Dunton CJ (2011) Reducing excessive toxicity in ovarian cancer treatment: a personalized approach. Future Oncol 7:789\u2013798","journal-title":"Future Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-014-0665-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-014-0665-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-014-0665-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T18:40:36Z","timestamp":1597430436000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-014-0665-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,29]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["665"],"URL":"https:\/\/doi.org\/10.1007\/s10147-014-0665-7","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,29]]}}}